Eseroline
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
Synonyms | Eseroline |
CAS Number | |
PubChem CID | |
ChemSpider | |
ChEBI | |
Chemical and physical data | |
Formula | C13H18N2O |
Molar mass | 218.295 g/mol |
3D model (JSmol) | |
| |
| |
(verify) |
Eseroline is a drug which acts as an opioid agonist.[1] It is a metabolite of the acetylcholinesterase inhibitor physostigmine but unlike physostigmine, the acetylcholinesterase inhibition produced by eseroline is weak and easily reversible,[2][3] and it produces fairly potent analgesic effects mediated through the μ-opioid receptor.[4] This mixture of activities gives eseroline an unusual pharmacological profile,[5][6] although its uses are limited by side effects such as respiratory depression[7] and neurotoxicity.[8]
References
- ↑ Fürst, S; Friedmann, T; Bartolini, A; Bartolini, R; Aiello-Malmberg, P; Galli, A; Somogyi, GT; Knoll, J (1982). "Direct evidence that eseroline possesses morphine-like effects". European Journal of Pharmacology. 83 (3–4): 233–41. PMID 6293841. doi:10.1016/0014-2999(82)90256-4.
- ↑ Jhamandas, K; Elliott, J; Sutak, M (1981). "Opiatelike actions of eseroline, an eserine derivative". Canadian Journal of Physiology and Pharmacology. 59 (3): 307–10. PMID 7194726.
- ↑ Galli, A; Renzi, G; Grazzini, E; Bartolini, R; Aiello-Malmberg, P; Bartolini, A (1982). "Reversible inhibition of acetylcholinesterase by eseroline, an opioid agonist structurally related to physostigmine (eserine) and morphine". Biochemical pharmacology. 31 (7): 1233–8. PMID 7092918. doi:10.1016/0006-2952(82)90009-0.
- ↑ Agresti, A; Buffoni, F; Kaufman, JJ; Petrongolo, C (1980). "Structure--activity relationships of eseroline and morphine: ab initio quantum-chemical study of the electrostatic potential and of the interaction energy with water". Molecular Pharmacology. 18 (3): 461–7. PMID 7464812.
- ↑ Galli, A; Ranaudo, E; Giannini, L; Costagli, C (1996). "Reversible inhibition of cholinesterases by opioids: possible pharmacological consequences". The Journal of pharmacy and pharmacology. 48 (11): 1164–8. PMID 8961166. doi:10.1111/j.2042-7158.1996.tb03914.x.
- ↑ Liu, WF (1991). "Effect of eseroline on schedule-controlled behavior in the rat". Pharmacology, Biochemistry, and Behavior. 38 (4): 747–51. PMID 1871191. doi:10.1016/0091-3057(91)90236-U.
- ↑ Berkenbosch, A; Rupreht, J; Degoede, J; Olievier, CN; Wolsink, JG (1993). "Effects of eseroline on the ventilatory response to CO2". European Journal of Pharmacology. 232 (1): 21–8. PMID 8458393. doi:10.1016/0014-2999(93)90723-U.
- ↑ Somani, SM; Kutty, RK; Krishna, G (1990). "Eseroline, a metabolite of physostigmine, induces neuronal cell death". Toxicology and applied pharmacology. 106 (1): 28–37. PMID 2251681. doi:10.1016/0041-008X(90)90102-Z.
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.